The study to develop novel treatment for antibody-mediated rejection after organ transplantation.
Not Applicable
- Conditions
- post-transplant antibody-mediated rejection
- Registration Number
- JPRN-UMIN000031863
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
The cases with active infection. The cases with viable malignancy, excluding hepatocellular carcinoma which is rescued by liver transplantation. Any cases which are considered as inadequate to entry the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitized cases: the incidence of negativity of antibody, or the change of antibody titer The cases with antibody-mediated rejection: organ function or pathological finding
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does the novel treatment target in post-transplant antibody-mediated rejection?
How does the experimental therapy compare to standard-of-care treatments like rituximab or eculizumab in managing antibody-mediated rejection?
Which biomarkers are used to identify patients likely to respond to the new treatment for antibody-mediated rejection?
What are the potential adverse events associated with the novel therapy for post-transplant antibody-mediated rejection and how are they managed?
Are there combination approaches or competitor drugs being explored alongside the intervention in JPRN-UMIN000031863 for organ transplant rejection?